

## Perspectives in Care

- 1243** Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes  
*A.G. Jones, T.J. McDonald, B.M. Shields, W. Hagopian, and A.T. Hattersley*

## Commentary

- 1252** Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes  
*G. Marquis-Gravel and J.-C. Tardif*

## Clinical Care/Education/Nutrition/Psychosocial Research

- 1254** Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes  
*A.R. Homer, F.C. Taylor, P.C. Dempsey, M.J. Wheeler, P. Sethi, M.K. Townsend, M.S. Grace, D.J. Green, N.D. Cohen, R.N. Larsen, B.A. Kingwell, N. Owen, and D.W. Dunstan*
- 1264** Spouse's Diabetes Status and Incidence of Depression and Anxiety: An 18-Year Prospective Study  
*J. Nielsen, S.A. Cunningham, M.K. Ali, and S.A. Patel*
- 1273** Cognitive Function in Adolescents and Young Adults With Youth-Onset Type 1 Versus Type 2 Diabetes: The SEARCH for Diabetes in Youth Study  
*A.L.B. Shapiro, D. Dabelea, J.M. Stafford, R. D'Agostino Jr., C. Pihoker, A.D. Liese, A.S. Shah, A. Bellatorre, J.M. Lawrence, L. Henkin, S. Saydah, and G. Wilkening, for the SEARCH for Diabetes in Youth Study Group*

## Epidemiology/Health Services Research

- 1281** Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis  
*D.K. Longmore, J.E. Miller, S. Bekkering, C. Saner, E. Mifsud, Y. Zhu, R. Saffery, A. Nichol, G. Colditz, K.R. Short, and D.P. Burgner, on behalf of the International BMI-COVID consortium*
- 1291** Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants  
*H. Claessen, M. Narres, T. Kvitkina, A. Wilk, H. Friedel, C. Günster, F. Hoffmann, M. Koch, K. Jandeleit-Dahm, and A. Icks*
- 1300** Trends in Receipt of American Diabetes Association Guideline-Recommended Care Among U.S. Adults With Diabetes: NHANES 2005–2018  
*J.-I. Shin, D. Wang, G. Fernandes, N. Daya, M.E. Grams, S.H. Golden, S. Rajpathak, and E. Selvin*
- 1309** Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study  
*I. Bebu, S. Keshavarzi, X. Gao, B.H. Braffett, A.J. Canty, W.H. Herman, T.J. Orchard, S. Dagogo-Jack, D.M. Nathan, J.M. Lachin, and A.D. Paterson, on behalf of the DCCT/EDIC Research Group*
- 1317** Incremental Dental Expenditures Associated With Diabetes Among Noninstitutionalized U.S. Adults Aged ≥18 Years Old in 2016–2017  
*Y. Chen, P. Zhang, E.T. Luman, S.O. Griffin, and D.B. Rolka*

## Emerging Therapies: Drugs and Regimens

- 1324** Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial  
*L. Qu, X. Liang, G. Tian, G. Zhang, Q. Wu, X. Huang, Y. Cui, Y. Liu, Z. Shen, C. Xiao, Y. Qin, H. Miao, Y. Zhang, Z. Li, S. Ye, X. Zhang, J. Yang, G. Cao, Y. Li, G. Yang, J. Hu, X. Wang, Z. Li, Y. Li, X. Zhang, G. Zhang, L. Chen, W. Hua, M. Yu, C. Lu, X. Zhang, and H. Jiang*
- 1334** Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial  
*Y.J.M. Op den Kamp, M. de Ligt, B. Dautzenberg, E. Kornips, R. Esterline, M.K.C. Hesselink, J. Hoeks, V.B. Schrauwen-Hinderling, B. Havekes, J. Oscarsson, E. Phielix, and P. Schrauwen*
- 1344** Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes  
*Y. Albogami, K. Cusi, M.J. Daniels, Y.-J.J. Wei, and A.G. Winterstein*
- 1353** Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial  
*D. Giugliano, M. Longo, P. Caruso, R. Di Fraia, L. Scappaticcio, M. Gicchino, M. Petrizzo, G. Bellastella, M.I. Maiorino, and K. Esposito*
- 1361** Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial  
*T.R. Pieber, R. Aronson, U. Hövelmann, J. Willard, L. Plum-Mörschel, K.M. Knudsen, B. Bandak, and R. Tehranchi*

## Emerging Technologies: Data Systems and Devices

- 1368** Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study  
*R. Roussel, J.-P. Riveline, E. Vicaut, G. de Pourville, B. Detournay, C. Emery, F. Levrat-Guillen, and B. Guerci*

## Pathophysiology/Complications

- 1377** ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes  
*Y. Abouleka, K. Mohammedi, C. Carpentier, S. Dubois, P. Gourdy, J.-F. Gautier, R. Roussel, A. Scheen, F. Alhenc-Gelas, S. Hadjadj, G. Velho, and M. Marre*

## Cardiovascular and Metabolic Risk

- 1385** The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study  
*J. Koska, R.Q. Migrino, K.C. Chan, K. Cooper-Cox, and P.D. Reaven*
- 1393** Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study  
*Y.-j. Choi, K.-D. Han, E.-K. Choi, J.-H. Jung, S.-R. Lee, S. Oh, and G.Y.H. Lip*

Keep up with the latest information for *Diabetes Care* and other ADA titles via Facebook ([/ADAJournals](#)) and Twitter ([@ADA\\_Journals](#)).

All articles in *Diabetes Care* are available online at [diabetes.org/diabetescare](http://diabetes.org/diabetescare). Cover articles (➡) and select content are available free of charge. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

ADA's *Diabetes Core Update* podcasts are available at [diabetesjournals.org](http://diabetesjournals.org) and through iTunes.

Icons shown below appear on the first page of an article if more information is available online.



Video



Podcast



Supplementary Data



Companion Article

**1402** Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes

*K.A. Sveen, K. Bech Holte, M. Svanteson, K.F. Hanssen, J. Nilsson, E. Bengtsson, and T. Julsrud Berg*

➡ **1410** A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

*A. Mariam, G. Miller-Atkins, K.M. Pantalone, R.S. Zimmerman, J. Barnard, M.W. Kattan, H. Shah, H.L. McLeod, A. Doria, M.J. Wagner, J.B. Buse, A.A. Motsinger-Reif, and D.M. Rotroff*

**1419** Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIABetes and LiFEstyle Cohort Twente (DIALECT)

*J.M. Beernink, M.M. Oosterwijk, K. Khunti, P. Gupta, P. Patel, J.F.M. van Boven, H.J. Lambers Heerspink, S.J.L. Bakker, G. Navis, R.M. Nijboer, and G.D. Laverman*

➡ **1426** Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study

*M. Zhao, L. Song, L. Sun, M. Wang, C. Wang, S. Yao, Y. Li, C. Yun, S. Zhang, Y. Sun, Z. Hou, S. Wu, and H. Xue*

➡ **1433** Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

*R. Nahra, T. Wang, K.M. Gadde, J. Oscarsson, M. Stumvoll, L. Jermutus, B. Hirshberg, and P. Ambery*

### Novel Communications in Diabetes

**1443** Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care



*C. Colling, S.J. Atlas, and D.J. Wexler*

**1447** The Rapid Transition to Telemedicine and Its Effect on Access to Care for Patients With Type 1 Diabetes During the COVID-19 Pandemic

*D.R. Tilden, K.A. Datye, D.J. Moore, B. French, and S.S. Jaser*

**1451** Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic

*L.C. Chao, A.P. Vidmar, and S. Georgia*

### Errata

**1454** Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? *Diabetes Care* 2031;44:641–646

*E. Ferrannini and J. Rosenstock*

**1455** Erratum. Relations Between Subclinical Disease Markers and Type 2 Diabetes, Metabolic Syndrome, and Incident Cardiovascular Disease: The Jackson Heart Study. *Diabetes Care* 2015;38:1082–1088

*V. Xanthakis, J.H. Sung, T.E. Samdarshi, A.N. Hill, S.K. Musani, M. Sims, K.A. Gharabeh, P.R. Liebson, H.A. Taylor, R.S. Vasan, and E.R. Fox*

**1456** Erratum. Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? *Diabetes Care* 2021;44:280–289

*H.L. Tanner, M. Dekker Nitert, L.K. Callaway, and H.L. Barrett*

**1457** Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. *Diabetes Care* 2021;44:1062–1069

*V. Ahuja, P. Aronen, T.A. Pramodkumar, H. Looker, A. Chetrit, A.H. Bloigu, A. Juutilainen, C. Bianchi, L. La Sala, R.M. Anjana, R. Pradeepa, U. Venkatesan, S. Jebarani, V. Baskar, T.V. Fiorentino, P. Timpel, R.A. DeFronzo, A. Ceriello, S. Del Prato, M. Abdul-Ghani, S. Keinänen-Kiukaanniemi, R. Dankner, P.H. Bennett, W.C. Knowler, P. Schwarz, G. Sesti, R. Oka, V. Mohan, L. Groop, J. Tuomilehto, S. Ripatti, M. Bergman, and T. Tuomi*

### Issues and Events

**1458** Issues and Events

### e-Letters – Observations

**e113** Is Shelter-in-Place Policy Related to Mail Order Pharmacy Use and Racial/Ethnic Disparities for Patients With Diabetes?

*T.W. Thomas, W.T. Dyer, M. Yassin, R. Neugebauer, A.J. Karter, and J.A. Schmittiel*

**e115** Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes

*T. Imafuku, H. Watanabe, K. Oniki, A. Yoshida, H. Kato, T. Nakano, K. Tokumaru, I. Fujita, N. Arimura, H. Maeda, Y. Sakamoto, N. Kondo, A. Morita, J. Saruwatari, M. Tanaka, K. Matsushita, T. Wada, M. Fukagawa, M. Otagiri, M.L. Fitzgerald, H. Jinnouchi, and T. Maruyama*

**e118** Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting

*L.E. Castellanos, C.A. Balliro, J.S. Sherwood, R. Jafri, M.A. Hillard, E. Greaux, R. Selagamsetty, H. Zheng, F.H. El-Khatib, E.R. Damiano, and S.J. Russell*

**e121** Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards

*H.K. Akturk, S. Agarwal, L. Hoffecker, and V.N. Shah*

**e124** Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor-Treated Type 2 Diabetes

*P.S. Hamblin, R. Wong, E.I. Ekinci, S. Sztal-Mazer, S. Balachandran, A. Frydman, T.P. Hanrahan, R. Hu, S.N. Ket, A. Moss, M. Ng, S. Ragunathan, and L.A. Bach*

**e127** Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study

*D. Scoccimarro, G. Cipani, I. Dicembrini, and E. Mannucci*

**e129** The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women

*L. Guo, N.P. Gordon, M. Chandra, O. Dayo, and J.C. Lo*

**e131** The Prevalence of Food Insecurity Is Highest Among Americans for Whom Diet Is Most Critical to Health

*J.B. Kirby, D. Bernard, and L. Liang*

**e133** Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic

*J. Valabhji, E. Barron, E.P. Vamos, K. Dhatriya, F. Game, P. Kar, A. Weaver, S. Verma, B. Young, and K. Khunti*

## e-Letters – Comments and Responses

- e136** Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. *Diabetes Care* 2020;43:3007–3015  
*S. Brikman and G. Dori*
- e137** Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. *Diabetes Care* 2020;43:3007–3015  
*I.J. Neeland, T. Kasaj, S.E. Inzuchi, B.S. Wojcick, H.K. Yaggi, and O.E. Johansen, on behalf of the EMPA-REG OUTCOME Investigators*
- e139** Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. *Diabetes Care* 2021;44:901–907  
*H.B. Østergaard, J. van der Leeuw, F.L.J. Visseren, and J. Westerink*
- e140** Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. *Diabetes Care* 2021;44:901–907  
*D. Vistisen, G.S. Andersen, A. Hulman, S.J. McGurnaghan, H.M. Colhoun, J.E. Henriksen, R.W. Thomsen, F. Persson, P. Rossing, and M.E. Jørgensen*